AI assistant
VYNE Therapeutics Inc. — Director's Dealing 2021
Sep 3, 2021
35290_dirs_2021-09-03_91158fe9-8fab-4345-a06b-229ff3d6a458.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VYNE Therapeutics Inc. (VYNE)
CIK: 0001566044
Period of Report: 2021-09-02
Reporting Person: Harsch Mutya (Chief Legal Officer and GC)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-09-02 | Common Stock | A | 60859 | $0.00 | Acquired | 166181 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-09-02 | Stock Options | $1.68 | A | 60860 | Acquired | 2031-09-02 | Common Stock (60860) | Direct |
Footnotes
F1: Represents an award of restricted stock units, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. 100% of the awards will vest on September 30, 2023, subject to the Reporting Person's continued service through the vesting date.
F2: 50% of the shares subject to the stock option award will vest on September 30, 2022, and the remaining 50% of the shares will vest thereafter in equal, quarterly installments, subject to the Reporting Person's continued service through the vesting date.